Biotest Aktiengesellschaft Net Asset Quality Index
Biotest Aktiengesellschaft net asset quality index. Biotest Aktiengesellschaft (BIO3) has a Net Asset Quality Index of 36.0% as of March 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €1.42 Billion minus total liabilities of €906.90 Million yields net assets of €509.60 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check BIO3 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Biotest Aktiengesellschaft (2002–2024)
Net asset quality index of Biotest Aktiengesellschaft from 2002 to 2024. This chart shows how Biotest Aktiengesellschaft's Net Asset Quality Index has evolved across 23 annual periods from 2002 to 2024. As of March 2025, the index stands at 36.0%, representing net assets of €509.60 Million against total assets of €1.42 Billion EUR. See BIO3 total equity for net asset value and shareholders' equity analysis.
Biotest Aktiengesellschaft Net Asset Quality Index by Year (2002–2024)
Biotest Aktiengesellschaft net asset quality index by year from 2002 to 2024. The table below presents the year-by-year Net Asset Quality Index for Biotest Aktiengesellschaft from 2002 to 2024, covering 23 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see BIO3 company net worth.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 37.0% | €530.70 Million | €1.43 Billion | €903.30 Million | ▲ +1.6 pp |
| 2023 | 35.4% | €498.90 Million | €1.41 Billion | €912.00 Million | ▲ +4.5 pp |
| 2022 | 30.8% | €371.10 Million | €1.20 Billion | €831.90 Million | ▼ -3.6 pp |
| 2021 | 34.5% | €380.40 Million | €1.10 Billion | €723.80 Million | ▼ -4.6 pp |
| 2020 | 39.0% | €441.60 Million | €1.13 Billion | €689.70 Million | ▼ -4.0 pp |
| 2019 | 43.0% | €476.90 Million | €1.11 Billion | €631.50 Million | ▼ -4.5 pp |
| 2018 | 47.5% | €495.20 Million | €1.04 Billion | €547.10 Million | ▲ +12.0 pp |
| 2017 | 35.5% | €347.80 Million | €978.50 Million | €630.70 Million | ▼ -3.1 pp |
| 2016 | 38.7% | €360.70 Million | €932.80 Million | €572.10 Million | ▼ -4.2 pp |
| 2015 | 42.8% | €412.30 Million | €962.70 Million | €550.40 Million | ▼ -3.7 pp |
| 2014 | 46.5% | €480.20 Million | €1.03 Billion | €552.40 Million | ▼ -5.5 pp |
| 2013 | 52.0% | €460.70 Million | €886.50 Million | €425.80 Million | ▼ -2.2 pp |
| 2012 | 54.1% | €369.43 Million | €682.35 Million | €312.91 Million | ▲ +3.4 pp |
| 2011 | 50.8% | €346.67 Million | €682.76 Million | €336.09 Million | ▲ +2.1 pp |
| 2010 | 48.6% | €307.61 Million | €632.34 Million | €324.73 Million | ▲ +6.0 pp |
| 2009 | 42.6% | €269.86 Million | €633.45 Million | €363.59 Million | ▼ -0.2 pp |
| 2008 | 42.8% | €253.37 Million | €592.04 Million | €338.67 Million | ▲ +0.7 pp |
| 2007 | 42.1% | €225.76 Million | €536.70 Million | €310.94 Million | ▼ -5.9 pp |
| 2006 | 47.9% | €179.31 Million | €374.01 Million | €194.69 Million | ▲ +1.9 pp |
| 2005 | 46.0% | €168.97 Million | €367.09 Million | €198.12 Million | ▲ +15.9 pp |
| 2004 | 30.1% | €107.97 Million | €358.27 Million | €250.31 Million | ▲ +0.6 pp |
| 2003 | 29.5% | €103.29 Million | €349.98 Million | €246.69 Million | ▼ -0.3 pp |
| 2002 | 29.8% | €110.79 Million | €371.99 Million | €261.20 Million | — |